Prof Nicholas James, Prof Karim Fizazi, Prof Matthew Smith, Prof Álvaro Pinto and Prof Mark Beresford meet at ESMO 2018 in Munich to discuss recent advances, and current challenges, in treating prostate cancer.
They discuss highlights from ESMO 2018, including the latest data from STAMPEDE suggesting men with low-metastatic risk prostate cancer may be eligible for radiotherapy, the updated results of a phase III trial of docetaxel-based chemotherapy in high-risk prostate cancer, and the combination of radium-233 with abiraterone acetate and prednisone/prednisolone in the ERA 223 trial.
Other key trials in prostate cancer include PROSPER and LATITUDE.
The challenges of progression risk and how to manage aggressive disease remain, though the advances seen in widening treatment options for different disease stages continues to offer hope for patients.
This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).